Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects With Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment With Surgery, Radiation and Temozolomide

NCT02014844 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT02014844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02014844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects With Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment With Surgery, Radiation and Temozolomide
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2014
Completion date
December 31, 2016
Enrollment
28 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma